In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated ...

GLP receptor agonists tied to lower substance use disorder risk in veterans, reducing emergency visits, hospitalizations, and overdose incidents.

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

GLP-1 RAs appear to be associated with lower all-cause mortality for patients living with type 2 diabetes and brain metastases.

In addition, GLP-1 receptor agonist initiation linked to reduced risks for SUD-related adverse events for people with preexisting SUD.

The researchers found that GLP-1 RA use was associated with significantly lower odds of vertebral compression fractures compared with nonuse. (HealthDay News) — Glucagon-like peptide 1 receptor ...

Initiation of GLP-1 receptor agonists was linked to fewer asthma exacerbations across overweight, obese, and morbidly obese patient cohorts.

Researchers at the University of Bristol have identified a specific biological mechanism by which GLP-1 drugs, the same class ...

Researchers have found that adults who stop taking GLP-1 receptor agonist drugs such as semaglutide and tirzepatide face a measurable increase in heart attack, stroke, and death risk within months of ...

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

Glucagon-like peptide-1 receptor agonist therapy with liraglutide or semaglutide is not associated with an increased risk for thyroid cancer among patients with type 2 diabetes or obesity, according ...

Among patients with cancer, brain metastases, and type 2 diabetes, GLP-1 use is associated with lower all-cause mortality, ...